Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT05148936
  4. Details
NCT05148936 Clinical Trial

Communities Fighting COVID-19!

Covid19 Clinical Trial

Official title:
Communities Fighting COVID!

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05148936
Other study ID # HS-2020-0186
Secondary ID 3U54CA132384-10S
Status Completed
Phase N/A
First received
Last updated
Start date October 25, 2020
Est. completion date August 25, 2023

Study information
Verified date June 2024
Source San Diego State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To create and evaluate effective COVID-19 testing uptake strategies that focus on underserved individuals who are exposed but have not accessed testing, and underserved individuals who are not routinely tested because they are unaware of their exposure or risk status in order to increase testing among these populations and reduce Covid-19 related disparities.

Description:

Communities Fighting COVID is a partnership between San Diego State's School of Public Health and numerous communities in San Diego focused on providing community-based testing to specific language-speaking communities and vulnerable populations. This partnership is funded by the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics-Undeserved Populations (Radx-UP), with the aim of ensuring all Americans have access to timely COVID-19 testing and diagnosis. Many communities, particularly immigrant and people of color communities, have a harder time accessing existing COVID-19 resources due to transportation, language barriers, or other barriers.

Recruitment information / eligibility
Status Completed
Enrollment 32750
Est. completion date August 25, 2023
Est. primary completion date August 25, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years to 120 Years
Eligibility Inclusion Criteria: - African American, Arabic speaking, Filipino, and Latino/a populations Exclusion Criteria: - Younger than 6, not in focus populations

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• COVID-19 Testing Home-based (Aim 1)
Implementation of Antigen and PCR testing at participant homes
• COVID-19 Testing Mobile (Aim 1)
Implementation of Antigen and PCR testing at mobile test sites
• COVID-19 Testing Mobile Approach 1 (Aim 2)
Implementation of Antigen and PCR testing at mobile test sites - active outreach
• COVID-19 Testing Mobile Approach 2 (Aim 2)
Implementation of Antigen and PCR testing at mobile test sites - baseline outreach

Locations
Country Name City State
United States Contact Households San Diego California

Sponsors (2)
Lead Sponsor Collaborator
San Diego State University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Test uptake Testing volume by study arm as cumulative count per hours testing site operated Through study completion, expected to be 20 months
Secondary Test access Proportion of individuals by study arm who note that this strategy has facilitated ability to test. Through study completion, expected to be 20 months
Secondary Test Impact (COVID-19 diagnoses) Proportion of COVID-19 diagnoses of those tested by study arm Through study completion, expected to be 20 months
Secondary Test Impact (number needed to screen) Number needed to screen (number tested in order to detect one new infection). Through study completion, expected to be 20 months
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3